Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 1999

View Archived Issues

Novel sublingual apomorphine: efficacy and tolerability in fluctuating Parkinson's disease

Lower mifepristone dose effective as emergency contraception

Biovail's Brexidol receives Canadian marketing approval

Ortho-Clinical Diagnostics and Chiron license HCV antigen test

Synthetic insulin mimetics designed at U. of Virginia

TGF-beta inhibitors for nephritis disclosed by Tsumura

Millennium discovers two novel proteins: Tango-72 and Tango-77

New salt of paroxetine with improved physicochemical characteristics

Peripheral cannabinoid receptor ligands in development at Japan Tobacco

Fujisawa synthesizes hypoglycemic sulfonamides

Hoechst's new MRI contrast agents

New ET receptor antagonist preserves coronary endothelial function in hypercholesterolemic pigs

Structure of Astra's next-generation proton pump inhibitor revealed for the first time

Chinese scientists design antitumor podophyllotoxin derivatives with high selectivity

Licensing opportunity from Yeda: VIP analogues for topical treatment of MED

MMP inhibitor from Pfizer attenuates LV enlargement following MI

Results from major clinical trial on new class of cardiovascular drugs reported at ACC meeting

Corixa's LeIF adjuvant is protected by three new U.S. patents

AstraZeneca merger makes progress with FTC; offer period extended

Xalatan approved in Japan for glaucoma and ocular hypertension

Phase I results with rFGF-2, bFGF in ischemic heart disease

Second prostate cancer study initiated with Multikine

New AZT derivatives with improved anti-HIV activity presented by Hughes Institute

Cardioprotective effects of JTV-519 involve specific activation of PKC isozyme

NeoTherapeutics begins Neotrofin clinical trials in Canada and Australia

Fujisawa decides not to enter Solarase licensing agreement with Hyal

Positive preliminary results from second CholestaGel phase III study

rPSGL-Ig: novel P-selectin antagonist from Genetics Institute as adjunct to thrombolytic therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...